tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Dec 13;10(12):2136.
doi: 10.3390/vaccines10122136.
Vaccine Preparedness for the Next Influenza Pandemic: A Regulatory Perspective
Norman W Baylor[SUP] 1 [/SUP], Jesse L Goodman[SUP] 2 [/SUP]
Affiliations
Abstract
The response to SARS-CoV-2 demonstrated the tremendous potential of investments in vaccine research and development to impact a global pandemic, resulting in the rapid development and deployment of lifesaving vaccines. However, this unprecedented speed was insufficient to either effectively combat initial waves of the pandemic or adapt in real time to new variants. This review focuses on opportunities from a public health oriented regulatory perspective for enhancing research, development, evaluation, production, and monitoring of safety and effectiveness to facilitate more rapid availability of pandemic influenza vaccines. We briefly review regulatory pathways and processes relevant to pandemic influenza, including how they can be strengthened and globally coordinated. We then focus on what we believe are critical opportunities to provide better approaches, tools, and methods to accelerate and improve vaccine development and evaluation and thus greatly enhance pandemic preparedness. In particular, for the improved vaccines needed to respond to a future influenza pandemic better and more rapidly, moving as much of the development and evaluation process as possible into the pre-pandemic period is critical, including through approval and use of analogous seasonal influenza vaccines with defined immune correlates of protection.
Keywords: SARS-CoV-2; pandemic influenza; regulatory; vaccines.
. 2022 Dec 13;10(12):2136.
doi: 10.3390/vaccines10122136.
Vaccine Preparedness for the Next Influenza Pandemic: A Regulatory Perspective
Norman W Baylor[SUP] 1 [/SUP], Jesse L Goodman[SUP] 2 [/SUP]
Affiliations
- PMID: 36560546
- DOI: 10.3390/vaccines10122136
Abstract
The response to SARS-CoV-2 demonstrated the tremendous potential of investments in vaccine research and development to impact a global pandemic, resulting in the rapid development and deployment of lifesaving vaccines. However, this unprecedented speed was insufficient to either effectively combat initial waves of the pandemic or adapt in real time to new variants. This review focuses on opportunities from a public health oriented regulatory perspective for enhancing research, development, evaluation, production, and monitoring of safety and effectiveness to facilitate more rapid availability of pandemic influenza vaccines. We briefly review regulatory pathways and processes relevant to pandemic influenza, including how they can be strengthened and globally coordinated. We then focus on what we believe are critical opportunities to provide better approaches, tools, and methods to accelerate and improve vaccine development and evaluation and thus greatly enhance pandemic preparedness. In particular, for the improved vaccines needed to respond to a future influenza pandemic better and more rapidly, moving as much of the development and evaluation process as possible into the pre-pandemic period is critical, including through approval and use of analogous seasonal influenza vaccines with defined immune correlates of protection.
Keywords: SARS-CoV-2; pandemic influenza; regulatory; vaccines.